BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer's Disease, CTAD, congress, held in Madrid, ...

Compound heterozygotes and complex cases had a higher frequency of abdominal pain, fever, arthralgia, arthritis, myalgia, and chest pain than subjects who were homozygous for E148Q, but none of these ...

Eligible patients are limited to apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers, which is a requirement for the class of currently approved amyloi Eli Lilly and Company (NYSE ...

Genetic polymorphisms have been described in the case of several CYP isoenzymes. The best explored example of this phenomenon is the CYP2C19 polymorphism. In this table the most frequent alleles ...

It allows one to discriminate the carriers of the trait, who presumably are heterozygotes, from carriers of the various cystinuric genotypes. The trait is expressed consistently with regard to ...

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years ...

In patients with protein C and protein S deficiency, when warfarin therapy is started there is a more rapid fall in concentration of protein C (antigen and activity) than the other vitamin K ...

"People around the world want and deserve access to treatment options for this disease. This approval in Great Britain is ...